CMS Open Payments · Program Year 2024
BonaliveInc
BonaliveInc reported $3,332.23 across General Payments, Research, and Ownership to 34 physicians and teaching hospitals across 34 transactions.
- $3.3K
- All-tracks total
- 34
- Transactions
- 34
- Recipients
- #1758
- of 1,925 companies
BonaliveInc reported $3,332.23 across all CMS Open Payments tracks (General + Research + Ownership) to 34 physicians and teaching hospitals in Program Year 2024 - ranking #1758 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $3,332.23, averaging $98.01 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer bonaliveinc BonaliveInc
$3.3K · #1758/1,925 · 0.0% industry · PY2024
- TOT $3.3K
- RANK #1758
- SHARE 0.0%
- TXN 34
- RCP 34
- CAT 1
- GEN $3.3K
- TOP1 5.4%
- PY 2024
Volume peers
Nearest volume peer: Meitheal Pharmaceuticals, Inc. ($3.3K)
BonaliveInc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for BonaliveInc
Rank #1758 of 1,925 companies in CMS Open Payments for 2024 belongs to BonaliveInc, which reported $3,332.23 across 34 transactions to 34 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $98.01 per transaction and $98.01 per recipient.
Of the 1 general-payment categories charted below, "Food and Beverage" is the largest at $3.3K across 34 transactions, 100.0% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Food and Beverage" leads BonaliveInc's 1-category general-payment breakdown at $3.3K, 100.0% of the reported total.
How BonaliveInc divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $3.3K | 34 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $710.36 (21.3%) of $3,332.23 in this company's General Payments records across 34 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for BonaliveInc
The five named recipients with the highest reported General Payments from this company
- 1
Dipak Balaji Ramkumar
$180.98 across 1 reported transactions
- 2
Christina J Gutowski
$151.18 across 1 reported transactions
- 3
William Ryan
$151.18 across 1 reported transactions
- 4
Chase Alexander Horsager
$113.51 across 1 reported transactions
- 5
Ivan Z Liu
$113.51 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as BonaliveInc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about BonaliveInc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with BonaliveInc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Northern X-Ray Company
Pillar Biosciences, Inc
Xiros Inc
Intersurgical Inc
Lifeward, Inc.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.